Facial/body flushing when first injected Injection site irritation and/or rash Joint and/or muscle pain Fatigue Pain and swelling after repeated shots to the same injection site- (rotate injection site ) In rare cases, some patients have experienced mild hypertension Water retention Warnings and precautions: CJC1295 and Ipamoralin peptides are banned by WADA (world anti-doping agency) for uses in sports CJC1295 may be mitogenic, if patient is prone to cancer and/or have cancer, use with caution CJC1295 may mask symptoms of hypothyroidism, make sure to test thyroid hormone levels (Free and Total T3, T4, TSH and thyroid antibodies) CJC1295 can cause Congestive Heart Failure, Do Not Use if you have a history of cardiac complications CJC1295 is a growth hormone releasing hormone (GHRH) analog= growth hormone mimetic
IMD, intermediodorsal nucleus of thalamus
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management, with some now specifically licensed for weight management in the UK
If you already have a sensitivity to sulfites, supplementing with glutathione can possibly increase the sulfites if you are deficient in molybdenum
Adam Abbs Medical Director * OASIS 4, 64-week study of adults with obesity using oral semaglutide 25mg alongside lifestyle changes
Backed by extensive research and FDA approval, it empowers patients to manage type 2 diabetes and achieve weight loss goals effectively
